Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 718 participants.

Also called NCT06236061

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 718 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06236061
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06236061. Randomized; triple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2025-05-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
Condition
Hypertension
Intervention (Drug)
LCZ
Intervention (Drug)
LCZ/AML 200 mg/2.5 mg
Intervention (Drug)
LCZ/AML 200 mg/5 mg
Intervention (Drug)
LCZ/AML 200 mg/10 mg
Intervention (Other)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06236061
Content hash
0dc9e88f931ac6caee118ecebac9e1e88b795d2a0adbaad811807ef9e135cdd4